Search Results

You are looking at 81 - 90 of 199 items for :

  • Refine by Access: All x
Clear All
Full access

Gary H. Lyman and Marek S. Poniewierski

) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients . Support Care Cancer 2013 ; 21 : 1487 – 1495 . 43. Talcott JA Siegel RD Finberg R . Risk assessment in cancer patients with fever and

Full access

Maxim Norkin and John R. Wingard

disseminated infection less commonly seen. Candida infections of the mucosa occur early and throughout the course of neutropenia and/or immunosuppressive therapy. Candida fungemia is rarely the cause of first neutropenic fever, but may be a cause of

Full access

Kimberly Davies, Matthew Barth, Saro Armenian, Anthony N. Audino, Phillip Barnette, Branko Cuglievan, Hilda Ding, James B. Ford, Paul J. Galardy, Rebecca Gardner, Rabi Hanna, Robert Hayashi, Alexandra E. Kovach, Andrea Judit Machnitz, Kelly W. Maloney, Lianna Marks, Kristin Page, Anne F. Reilly, Joanna L. Weinstein, Ana C. Xavier, Nicole R. McMillian, and Deborah A. Freedman-Cass

expert opinion. The complete details of the development and update of the NCCN Guidelines are available on the NCCN website ( NCCN.org ). Initial Presentation Patients with DLBCL and BL may present with fever, chills, night sweats, unexplained

Full access

Jeffrey A. Gilreath, David D. Stenehjem, and George M. Rodgers

be given in 1 to 4 injections for children with iron-deficiency anemia. This method was appealing to clinicians because the reported incidence of reactions was on the order of only 1% and included symptoms such as fever, arthralgia, and

Full access

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz, Mary A. Dwyer, and Hema Sundar

GCSFs might be considered in patients with severe neutropenic fever after chemotherapy. HBV Reactivation: HBV reactivation leading to fulminant hepatitis, hepatic failure, and death have been reported in patients receiving chemotherapy and

Full access

cancer survivors between time points and distress the areas of eating ( P <.04), fatigue ( P <.01), fevers ( P <.02), getting around ( P <.05), mouth sores ( P <.05), congestion ( P <.02), sleep ( P <.02), fears ( P =.05), nervousness ( P =.04), physical

Full access

Nora Janjan

be better for other physical symptoms, such as fever, and the absence of a symptom. 22 , 23 Data capture of PROs enables health care providers to evaluate the adequacy of CRP control, especially that of breakthrough pain, for individual patients

Full access

Venkata K. Pokuri, Mihai Merzianu, Shipra Gandhi, Junaid Baqai, Thom R. Loree, and Seema Bhat

marrow, and gastrointestinal tract); the remaining patients presented with both nodal and extranodal disease. 8 Systemic symptoms (fever, night sweats, weight loss, and fatigue) were uncommon and mostly occurred in patients with both nodal and extranodal

Full access

Iulia Giuroiu and Diane Reidy-Lagunes

important to minimize treatment-related adverse effects, which can include pain, nausea, fever, fatigue, and liver abnormalities. Systemic Cytotoxic Therapy Treatment No clearly defined role currently exists for conventional chemotherapy in the

Full access

Matthew Zibelman and Anthony J. Olszanski

, dysphagia, or dyspnea. He reported no significant weight loss, fevers, or chills, and had not noticed any other masses or unusual skin lesions. He did report mild fatigue. A brief trial of antibiotics was prescribed by a primary care physician but did not